Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MRNA Stock Forecast 2026-2027
$53.39
Current Price
$21.09B
Market Cap
Buy 3
Hold 18
Sell 3
Wall St Analyst Ratings
Distance to MRNA Price Targets
+152.9%
To High Target of $135.00
-27.9%
To Median Target of $38.50
-77.5%
To Low Target of $12.00
MRNA Price Momentum
+1.7%
1 Week Change
+26.4%
1 Month Change
+55.7%
1 Year Change
+81.0%
Year-to-Date Change
-10.3%
From 52W High of $59.55
+139.6%
From 52W Low of $22.28
📊 TOP ANALYST CALLS
Did MRNA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Moderna is one of their latest high-conviction picks.
Latest MRNA Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, MRNA has a neutral consensus with a median price target of $38.50 (ranging from $12.00 to $135.00). The overall analyst rating is Buy (6.1/10). Currently trading at $53.39, the median forecast implies a -27.9% downside. This outlook is supported by 3 Buy, 18 Hold, and 3 Sell ratings.
The most optimistic forecast comes from Luca Issi at RBC Capital, projecting a 152.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MRNA Analyst Ratings
3
Buy
18
Hold
3
Sell
MRNA Price Target Range
Low
$12.00
Average
$38.50
High
$135.00
Current: $53.39
Latest MRNA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MRNA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 23, 2026 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $69.00 |
| Feb 17, 2026 | Evercore ISI Group | Cory Kasimov | In-Line | Maintains | $35.00 |
| Feb 17, 2026 | Goldman Sachs | Salveen Richter | Neutral | Maintains | $41.00 |
| Feb 17, 2026 | RBC Capital | Luca Issi | Sector Perform | Maintains | $30.00 |
| Jan 7, 2026 | UBS | Eliana Merle | Neutral | Assumes | $34.00 |
| Dec 12, 2025 | Jefferies | Andrew Tsai | Hold | Initiates | $30.00 |
| Dec 12, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $28.00 |
| Nov 21, 2025 | Leerink Partners | Mani Foroohar | Underperform | Maintains | $18.00 |
| Nov 21, 2025 | RBC Capital | Luca Issi | Sector Perform | Maintains | $25.00 |
| Nov 21, 2025 | Piper Sandler | Edward Tenthoff | Overweight | Reiterates | $63.00 |
| Nov 10, 2025 | B of A Securities | Dimple Gosai | Underperform | Maintains | $21.00 |
| Nov 7, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $25.00 |
| Oct 23, 2025 | UBS | Eliana Merle | Buy | Maintains | $40.00 |
| Oct 23, 2025 | JP Morgan | Jessica Fye | Underweight | Maintains | $25.00 |
| Oct 23, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $28.00 |
| Oct 20, 2025 | Needham | Joseph Stringer | Hold | Reiterates | $N/A |
| Oct 10, 2025 | Morgan Stanley | Matthew Harrison | Equal-Weight | Maintains | $32.00 |
| Aug 22, 2025 | Leerink Partners | Mani Foroohar | Underperform | Maintains | $15.00 |
| Aug 4, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $31.00 |
| Jul 22, 2025 | B of A Securities | Dimple Gosai | Underperform | Maintains | $25.00 |
Moderna, Inc. (MRNA) Competitors
The following stocks are similar to Moderna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Moderna, Inc. (MRNA) Financial Data
Moderna, Inc. has a market capitalization of $21.09B with a P/E ratio of 25.0x. The company generates $1.94B in trailing twelve-month revenue with a -145.2% profit margin.
Revenue growth is -29.8% quarter-over-quarter, while maintaining an operating margin of -126.4% and return on equity of -28.9%.
Valuation Metrics
Market Cap
$21.09B
Enterprise Value
$16.59B
P/E Ratio
25.0x
PEG Ratio
-0.9x
Price/Sales
10.8x
Growth & Margins
Revenue Growth (YoY)
-29.8%
Gross Margin
+33.1%
Operating Margin
-126.4%
Net Margin
-145.2%
EPS Growth
-29.3%
Financial Health
Cash/Price Ratio
+27.5%
Current Ratio
3.3x
Debt/Equity
15.1x
ROE
-28.9%
ROA
-14.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Moderna, Inc. (MRNA) Business Model
About Moderna, Inc.
What They Do
Biotechnology company specializing in mRNA medicines.
Business Model
The company focuses on researching and developing innovative therapeutics and vaccines utilizing its proprietary mRNA technology. It generates revenue primarily through the sale of its mRNA-based products, including its COVID-19 vaccine Spikevax, as well as other vaccines and therapies currently in clinical development.
Additional Information
Moderna has a robust pipeline with over 40 clinical-stage products, targeting various diseases such as infectious, oncological, and rare conditions. The company's advancements in mRNA technology position it as a leader in precision medicine and as a key player in responding to public health challenges, including pandemics.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
4,700
CEO
Mr. Stéphane Bancel M.B.A.
Country
United States
IPO Year
2018
Website
www.modernatx.comModerna, Inc. (MRNA) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS
Moderna jumps after $2.25B settlement with Genevant and Arbutus over LNP patents tied to its COVID-19 and RSV vaccines, ending global litigation.
Mar 04, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Moderna, Inc. (MRNA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
3 days ago
Quick Summary
Moderna, Inc. (MRNA) presented at the Barclays 28th Annual Global Healthcare Conference, providing insights into its business and future plans.
Why It Matters
Moderna's presentation at a major healthcare conference could signal new developments or partnerships, influencing stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
FDA Commissioner Marty Makary announced that Dr. Vinay Prasad, head of the Center for Biologics Evaluation and Research, will depart from his role in April.
Why It Matters
Leadership changes at the FDA, particularly in key areas like biologics, can impact regulatory processes and timelines, influencing biotech stock volatility and investment strategies.
Source: Benzinga
Market Sentiment:
Neutral
Quick Summary
Moderna (NASDAQ: MRNA) shares rose 12% in the past week and 95% year-to-date, trading at approximately $56.67 as of March 4, 2026.
Why It Matters
Moderna's significant share price increase signals strong investor confidence, potentially indicating robust financial performance or positive developments in its products, impacting investment decisions.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Moderna stock rose late Friday following reports of the impending resignation of FDA's top vaccine official, Vinay Prasad, amid industry concerns.
Why It Matters
Moderna's stock surge indicates positive market sentiment, potentially reflecting investors' confidence in the company's vaccine prospects amid regulatory changes.
Source: Investors Business Daily
Market Sentiment:
Negative
Quick Summary
The FDA has denied or discouraged at least eight new drug applications over the past year, including a reversal on reviewing Moderna's flu shot.
Why It Matters
The FDA's trend of denying new drug applications may signal regulatory tightening, impacting biotech companies' growth prospects and investor confidence in the pharmaceutical sector.
Source: CNBC
Market Sentiment:
Negative
Quick Summary
Wall Street is evaluating three volatile stocks for 2026: Moderna (MRNA), Strategy (MSTR), and Trade Desk (TTD), each showing distinct market outlooks.
Why It Matters
Differing market views on Moderna, MicroStrategy, and Trade Desk indicate varied investor sentiment and potential volatility, influencing investment strategies and risk assessments.
Source: 24/7 Wall Street
Market Sentiment:
Negative
Frequently Asked Questions About MRNA Stock
What is Moderna, Inc.'s (MRNA) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Moderna, Inc. (MRNA) has a median price target of $38.50. The highest price target is $135.00 and the lowest is $12.00.
Is MRNA stock a good investment in 2026?
According to current analyst ratings, MRNA has 3 Buy ratings, 18 Hold ratings, and 3 Sell ratings. The stock is currently trading at $53.39. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MRNA stock?
Wall Street analysts predict MRNA stock could reach $38.50 in the next 12 months. This represents a -27.9% decrease from the current price of $53.39. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Moderna, Inc.'s business model?
The company focuses on researching and developing innovative therapeutics and vaccines utilizing its proprietary mRNA technology. It generates revenue primarily through the sale of its mRNA-based products, including its COVID-19 vaccine Spikevax, as well as other vaccines and therapies currently in clinical development.
What is the highest forecasted price for MRNA Moderna, Inc.?
The highest price target for MRNA is $135.00 from Luca Issi at RBC Capital, which represents a 152.9% increase from the current price of $53.39.
What is the lowest forecasted price for MRNA Moderna, Inc.?
The lowest price target for MRNA is $12.00 from at , which represents a -77.5% decrease from the current price of $53.39.
What is the overall MRNA consensus from analysts for Moderna, Inc.?
The overall analyst consensus for MRNA is neutral. Out of 30 Wall Street analysts, 3 rate it as Buy, 18 as Hold, and 3 as Sell, with a median price target of $38.50.
How accurate are MRNA stock price projections?
Stock price projections, including those for Moderna, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 13, 2026 1:58 PM UTC